(Q42993893)

12 November 2017

Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon (English)

1 reference

12 November 2017

0 references

1 reference

1 reference

1 reference

6

1 reference

12 November 2017

O Reichard

1

1 reference

12 November 2017

H Glaumann

2

1 reference

12 November 2017

A Frydén

3

1 reference

12 November 2017

G Norkrans

4

1 reference

12 November 2017

R Wejstål

5

1 reference

12 November 2017

language of work or name

1 reference

1 May 1999

1 reference

12 November 2017

Journal of Hepatology

1 reference

12 November 2017

30

1 reference

12 November 2017

783-787

1 reference

12 November 2017

5

1 reference

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

12 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Treatment of chronic hepatitis C with amantadine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Eradication of hepatitis C virus RNA after alpha-interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Long-term course of interferon-treated chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B posttransfusion hepatitis: no correlation of outcome to presence of hepatitis C virus antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Detection of hepatitis C virus (HCV) RNA by PCR related to HCV antibodies in serum and liver histology in Swedish blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Colorimetric detection of competitive PCR products for quantification of hepatitis C viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Genotyping of hepatitis C virus isolates by a modified polymerase chain reaction assay using type specific primers: epidemiological applications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Classification of chronic viral hepatitis: a need for reassessment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Therapy of hepatitis C: overview

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2899%2980129-9

7 January 2021

10.1016/S0168-8278(99)80129-9

Identifiers

DOI

1 reference

12 November 2017

1 reference